ALBERTDAVDBSEAlbert David Ltd-$HighNeutral
Announced Tue, 12 May · 18:46 IST

Financial Results for the Fourth quarter and year ended 31st March, 2026

Ceo Appointed ExternalManagement Changes View source PDF

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-10.5%1-day move
₹790.00
prior close
₹730.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-1.9-2.3-2.1-10.5-8.6-10.1-9.2-10.4-10.6-8.8-8.3-11.2
Up moveDown movePending
AI summary

Albert David Limited reported audited FY2026 results with revenue from operations at Rs 33,359.81 Lacs (vs Rs 34,576.80 Lacs prior year), a marginal decline. The company swung to a net loss of Rs 149.47 Lacs for the year compared to a net profit of Rs 1,720.08 Lacs in FY2025, largely due to lower other income (Rs 745.33 Lacs vs Rs 2,958.07 Lacs). Profit before tax dropped sharply to Rs 52.49 Lacs from Rs 2,522.77 Lacs. The Board appointed Mr. Amit Mahla as CEO effective May 12, 2026, filling a vacancy since Mr. Umesh Manohar Kunte resigned as Managing Director & CEO on December 18, 2025. Mr. Mahla brings 28+ years of pharma experience from companies including Cipla, Sun Pharma, and JB Pharma. A final dividend of Rs 5 per share (50% on Rs 10 face value) has been recommended, subject to shareholder approval at the August 6, 2026 AGM. Statutory auditors L.B. Jha & Co. issued an unmodified opinion.

Likely market impact

The significant profit decline and net loss for FY2026 may weigh on investor sentiment. The appointment of an experienced external CEO may provide stability going forward. The 50% dividend payout signals confidence despite weak profitability.